LifeMD price target raised to $18 from $12 at Lake Street

Lake Street analyst Brooks O’Neil raised the firm’s price target on LifeMD (LFMD) to $18 from $12 and keeps a Buy rating on the shares. LifeMD is building a national, tech-enabled virtual care platform spanning primary care, weight management, men’s and women’s health, hormone therapy, and behavioral health, and with strong early traction, the company is scaling efficiently, the analyst tells investors in a research note.